Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.315
-0.005 (-0.22%)
Apr 29, 2026, 9:50 AM EDT - Market open

Galectin Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-30.84-47.05-41.07-38.78-30.53
Upgrade
Depreciation & Amortization
0.050.040.030.030.04
Upgrade
Stock-Based Compensation
1.662.452.262.872.08
Upgrade
Other Operating Activities
4.640.511.13-0.150.15
Upgrade
Change in Accounts Payable
-6.04-2.072.674.243.69
Upgrade
Change in Other Net Operating Assets
6.654.362.010.720.27
Upgrade
Operating Cash Flow
-23.88-41.77-32.97-31.06-24.31
Upgrade
Long-Term Debt Issued
2130301030
Upgrade
Net Debt Issued (Repaid)
2130301030
Upgrade
Issuance of Common Stock
5.481.2310.03-6.81
Upgrade
Financing Cash Flow
26.4831.2340.031036.81
Upgrade
Net Cash Flow
2.6-10.547.07-21.0612.51
Upgrade
Levered Free Cash Flow
-20.9-29.31-20.68-17.56-13.23
Upgrade
Unlevered Free Cash Flow
-16.32-25.84-18.93-16.91-12.92
Upgrade
Change in Working Capital
0.612.284.684.973.96
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.